Pfizer and Eli Lilly’s tanezumab for osteoarthritis (OA) of the hip and knee...
- Researchers uncover pathogenic mechanism causing IPF
- Study shows methylphenidate is most effective ADHD drug for under-16s
- The next generation of antimalarials
- Researchers claim to have uncovered how thalidomide caused birth defects
- Medicines for Malaria Venture: steps towards eliminating a global scourge
NUI Galway finds new treatment strategy for breast cancer relapse
Irish researchers have discovered a new treatment strategy to enhance the response to chemotherapy and minimise the risk of relapse for triple negative breast cancer (TNBC) patients.
RXi and Karolinska Institutet target solid tumour therapy
US-based biotechnology company RXi Pharmaceuticals has formed a research alliance with Karolinska Institutet in Stockholm, Sweden to improve immuno-oncology treatments for solid tumours.
NIH-funded study reverses congenital blindness in mice
A new study funded by the National Institutes of Health (NIH) National Eye Institute (NEI) has successfully reversed congenital blindness by changing the supportive Müller glia cells in the retina into rod photoreceptors.
Mustang Bio licenses gene therapy for bubble boy disease
US-based biopharmaceutical firm Mustang Bio has entered an exclusive worldwide licence agreement with St. Jude Children’s Research Hospital for a new gene therapy to treat X-linked severe combined immunodeficiency (X-SCID or bubble boy disease).
Shire submits NDA in Japan for Intuniv to treat ADHD
Irish biotechnology company Shire, through its partner Shionogi, has filed a new drug application (NDA) in Japan seeking approval to manufacture and market its Intuniv medicine for the treatment of adults with attention deficit hyperactivity disorder (ADHD).
Pfizer/Lilly’s Phase III trial for tanezumab in osteoarthritis still draws caution
Pfizer and Eli Lilly’s tanezumab for osteoarthritis (OA) of the hip and knee may face hurdles to clear long-term efficacy and safety benchmarks.
Onpattro approved by FDA as first treatment for polyneuropathy
Alnylam Pharmaceuticals has obtained approval from the US Food and Drug Administration (FDA) for Onpattro (patisiran) to treat peripheral nerve disease (polyneuropathy) in adults with hereditary transthyretin-mediated amyloidosis (hATTR).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.